• Eli Lilly shares tumbled nearly 14%, marking their steepest single-day drop since August 2000.
  • The sell-off followed mixed late-stage trial results for oral obesity drug orforglipron, despite strong Q2 earnings.
  • Company maintains bullish outlook with raised full-year guidance, but market reaction highlights high expectations for obesity treatments.

A Bitter Pill for Investors

Eli Lilly & Co. investors swallowed a hard reality check Thursday as shares cratered 13.8% to $714.32 - their worst daily performance in 23 years. The dramatic drop came despite the pharmaceutical giant posting better-than-expected second quarter earnings, underscoring how sky-high expectations for its obesity drug pipeline can overshadow even strong financial performance.

The trigger? Top-line results from a Phase 3 trial of experimental oral obesity treatment orforglipron showed patients on the highest dose lost 12-14% of body weight. While clinically meaningful, these figures failed to match the blockbuster potential priced into Lilly's valuation. "The Street wanted home runs, and they got solid doubles," said one healthcare portfolio manager who asked not to be named discussing individual positions.

Earnings Strength Overshadowed

Ironically, the selloff occurred against a backdrop of robust financials. Lilly reported Q2 revenue of $8.31 billion, beating consensus estimates by $190 million, powered by diabetes drug Mounjaro's 72% sales jump to $2.39 billion. The company raised full-year guidance to $60-62 billion in revenue and $21.75-23.00 in adjusted EPS.

"This reaction speaks to the bifurcated narrative around Lilly," noted Bernstein analyst Aaron Gal, who maintains an Outperform rating. "The core business is firing on all cylinders, but investors are paying premium multiples specifically for obesity upside." At Thursday's close, Lilly's market cap stood at $678 billion - down $108 billion from Wednesday but still up 26% year-to-date.

What Comes Next

Management sought to calm nerves on the earnings call, emphasizing orforglipron's competitive profile as a convenient oral alternative to injectable rivals. "We see this as an important option for patients who prefer pills over injections," said CFO Anat Ashkenazi. The company expects to submit the drug for FDA approval in late 2025.

Analysts noted the reaction may be overdone given Lilly's broader pipeline, including next-generation obesity treatments still in development. But with the stock trading at 47x forward earnings before the drop, even minor stumbles were bound to trigger outsized moves. As one trader put it: "When you're priced for perfection, good isn't good enough."